PSILERA BIOSCIENCE
Psilera Bioscience reimagining psychoactive natural products as building blocks for a new generation of mindful medicine. Many pharmaceutical drugs originate from nature due to intrinsic biodiversity, biological activity, and safety that have been optimized throughout time. A shift towards natural products is evident from significant interest and clinical data identifying cannabis and psychedelics as emerging therapeutics. Psilera will leverage its research strength being led by executives from ... the pharmaceutical and cannabis industries to develop a best-in-class IP portfolio of analogs based on psychoactive precursors. Lead compounds are formulated and screened against neurological targets to evaluate clinical potential with pipeline candidates in the areas of mood disorders, cognitive diseases, and addiction. Psilera’s mission is to make a significant impact on mental health and reduce human suffering.
PSILERA BIOSCIENCE
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2019-07-01
Address:
Tampa, Florida, United States
Country:
United States
Website Url:
http://www.psilera.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.63 M USD
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
hC Bioscience
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
Tierra Biosciences
Tierra Biosciences is a synthetic biology company that offers an AI-driven platform with a vast range of custom proteins for research.
Current Advisors List
Current Employees Featured
Founder
Investors List
Florida High Tech
Florida High Tech investment in Grant - Psilera Bioscience
Baird Inc
Baird Inc investment in Seed Round - Psilera Bioscience
Iter Investments
Iter Investments investment in Seed Round - Psilera Bioscience
What If Ventures
What If Ventures investment in Seed Round - Psilera Bioscience
JLS Fund
JLS Fund investment in Seed Round - Psilera Bioscience
Receptor
Receptor investment in Seed Round - Psilera Bioscience
Official Site Inspections
http://www.psilera.com
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Psilera Bioscience"
Psilera Bioscience - Psychedelic Science Review
Psilera Bioscience Psilera is a biotechnology firm using psychedelic compounds as building blocks to synthesize new medications for mental health and central nervous system disorder treatment. The company was co-founded in 2019 by … See details»
Psilera - Crunchbase Company Profile & Funding
Psilera is a biopharmaceutical company focused on developing groundbreaking therapeutics for neurodegenerative diseases by creating a new class of neurological medicines. See details»
Psilera Company Profile | Management and Employees List
Psilera Profile and History Psilera is a leading psychedelic-based biotechnology company with leadership from the pharmaceutical and science-driven cannabis industries to innovate new … See details»
Psilera 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Psilera. Use the PitchBook Platform to explore the full profile. See details»
Psilera Biosciences - Neuly
Psilera Biosciences A privately held company Tampa, Florida, USA https://www.psilera.com Therapy Development Research DMT See details»
Psilera Information - RocketReach
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, … See details»
Psilera company information, funding & investors | New York State ...
Psilera, creating new drugs using a proprietary in-house drug discovery engine. Here you'll find information about their funding, investors and team. See details»
Company
Founded in 2019, Psilera is a scientist lead, female co-founded biotechnology research company that specializes in early-stage drug discovery & development to provide new neurological therapies to underserved patient populations. See details»
Psilera - VentureRadar
"Psilera is a leading biotechnology company developing proprietary neuromodulators based on traditionally psychoactive compounds targeting mental health disorders. Psilera's cutting edge … See details»
Psilera - Company Profile - Tracxn
Jan 27, 2025 Psilera - Manufacturer of natural-based medicines for the treatment of mental health illnesses. Raised a total funding of $2.5M over 1 round from 4 investors. See details»
Psilera Bioscience: Developing the Next Generation of Safer, …
Oct 14, 2020 Psilera Bioscience, a biotech firm focused on early-stage drug discovery and development, is on the cutting edge of this growth. A scientist owned and operated company … See details»
Approach - PSILERA
Psilera’s Third Eyeâ„¢ The data feedback loop that sets Psilera apart. Psilera’s proprietary Third Eyeâ„¢ drug screening platform enables our team of computational chemists, data scientists, … See details»
Psilera - Funding, Financials, Valuation & Investors - Crunchbase
Psilera is funded by 7 investors. Mystic Ventures and Florida High Tech Corridor are the most recent investors. Which investors participated in the most funding rounds? Show See details»
Psilera creates a new era of mindful medicine
Dec 12, 2021 Psilera was founded by two PhD natural product chemists in July 2019. Having witnessed the cannabis industry first-hand, the founders realized the potential of psychedelics … See details»
Psilera: No Trip Approach To Mental Health & Dementia
Feb 1, 2024 Psilera’s lead clinical candidate is PSIL-006, a non-hallucinogenic psychedelic compound and potential breakthrough for neurodegenerative disorders. See details»
Psilera’s New Compounds Show Potential for Significant …
Aug 10, 2022 PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic … See details»
News & Insights - PSILERA
Psilera’s focus on creating non-hallucinogenic neuroplastogens was of particular interest to Slomowitz and illustrates how we as a company are evolving within the industry to meet the … See details»
Clenera Announces Leadership Transition: Jared McKee Appointed …
18 hours ago Clenera announces leadership transition with Jared McKee as new CEO and Adam Pishl becoming Vice Chair of the Board. See details»
PSIL-006
PSIL-006 is a next-generation, psilocybin derivative with broad applicability and a patient-friendly profile. Because of its non-hallucinogenic profile, PSIL-006 is designed to be a good candidate … See details»
Resources - psilera.com
At Psilera, we believe patients and caregivers deserve access to the latest information to make informed treatment decisions. Check out these resources for additional information on FTD … See details»